Oncogenes y Dianas Efectoras
PANCCUN
NewYork–Presbyterian Hospital
Nueva York, Estados UnidosPublications en collaboration avec des chercheurs de NewYork–Presbyterian Hospital (1)
2020
-
BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial
Nature Medicine, Vol. 26, Núm. 6, pp. 878-885